CAMP4 Therapeutics announces up to $100M private placement and board changes

Camp4 Therapeutics Corp

Initial closing raises $50M from 26.7M shares at $1.53/share, pre-funded warrants, and management shares; total upfront proceeds ~$50M.
Second closing of up to $50M contingent on regulatory clearance for SYNGAP1 trial and stock price milestone or waiver.
Directors James Boylan, Ravi Thadhani, and Paula Ragan resigned; Doug Williams appointed Board Chair.
Daniel Tardiff elevated to Chief Scientific Officer effective October 1, 2025.
Financing led by Coastlands Capital with Janus Henderson, Balyasny, Vivo Capital, 5AM Ventures and others.

item 1.01item 3.02item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.